Your prediction
Takeda Pharmaceutical Co Ltd Stock
A very strong showing by Takeda Pharmaceutical Co Ltd today, with an increase of €0.84 (3.010%) compared to yesterday's price.
Our community identified positive and negative aspects for Takeda Pharmaceutical Co Ltd stock for the coming years. 1 users see the criterium "Business model" as a plus for the Takeda Pharmaceutical Co Ltd stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Takeda Pharmaceutical Co Ltd in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Takeda Pharmaceutical Co Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 3.010% | 2.122% | 8.053% | 9.194% | 6.771% | -4.777% | -5.406% |
| Chugai Pharmaceutical Co Ltd | 4.700% | 1.094% | -0.066% | 14.829% | 0.644% | 85.352% | 2.027% |
| Daiichi Sankyo Co Ltd | 2.730% | -7.151% | -10.531% | -41.646% | -12.996% | -48.198% | -42.065% |
| Dainippon Sumitomo Pharma | -4.100% | -0.800% | -1.587% | 256.322% | -0.800% | 98.400% | 1.639% |
Comments
News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
